share_log

Quanterix to Participate at the Scotiabank Healthcare 1x1 Day

Quanterix to Participate at the Scotiabank Healthcare 1x1 Day

quanterix将参加Scotiabank Healthcare 1x1 Day活动
Quanterix ·  06/17 00:00

BILLERICA, Mass.--(BUSINESS WIRE)--Jun. 17, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer, Masoud Toloue, and Chief Financial Officer, Vandana Sriram, will attend the Scotiabank Healthcare 1x1 Day on June 20, 2024.

美国马萨诸塞州比勒里卡--(商业线)--2024年6月17日--Quanterix公司(纳斯达克:QTRX)是一家通过超灵敏生物标志物检测推动科学发现的公司,今天宣布,首席执行官Masoud Toloue和首席财务官Vandana Sriram将于2024年6月20日参加Scotiabank Healthcare 1x1 Day。

To learn more about Quanterix, visit www.quanterix.com/company. To learn more about Quanterix's Simoa technology, visit www.quanterix.com/simoa-technology.

要了解更多有关Quanterix的信息,请访问www.quanterix.com/company要了解有关Quanterix Simoa技术的更多信息,请访问www.quanterix.com/simoa-technology.

About Quanterix

关于Quanterix

From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.

从探索到诊断,Quanterix的超敏生物标记物检测通过其无与伦比的灵敏度和适应性推动了突破。该公司的Simoa技术提供了血液、血清或血浆中更早期生物标志物检测的黄金标准,能够量化远低于检测限(LoQ)的蛋白质。其行业领先的精密仪器、数字免疫测定技术和CLIA认证的Accelerator实验室支持了神经学、肿瘤学、免疫学、心脏病学和传染病领域的疾病认知和管理的研究。Quanterix已成为科学界近20年的可靠合作伙伴,支持在2900多个同行评审期刊上发表的研究。在位于马萨诸塞州比勒利卡的该公司网站上查找有关该公司的其他信息https://www.quanterix.com或关注我们的推特和页面。LinkedIn.

Media Contact:
PAN Communications
Maya Nimnicht
510-334-6273
quanterix@pancomm.com

媒体联系人:
PAN通讯
Maya Nimnicht
510-334-6273
quanterix@pancomm.com

Investor Relations Contact:
Quanterix
Francis Pruell
(508)-789-1725
ir@quanterix.com

投资者关系联系方式:
Quanterix
Francis Pruell
(508)-789-1725
ir@quanterix.com

Source: Quanterix Corporation

来源:quanterix公司

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发